title: Focal bone lesions in HIV-positive patient treated with tenofovir.
abstract: BACKGROUND
  Tenofovir is a widely used antiviral drug for the treatment of HIV and HBV infection. Although its side effects on renal function and bone metabolism are well known, there are no reports on focal bone lesions caused by this drug. Our case suggests this new, unusual but important scenario.
  
  
  METHODS
  We report on a 46-year-old HIV-positive man treated with an antiretroviral regimen containing tenofovir who suddenly developed localized inflammatory bone lesions. The examinations performed ruled out all the disorders commonly associated with this clinical pattern, and the patient's conditions improved only after the suspension of tenofovir.
  
  
  CONCLUSIONS
  The case study suggests a rare but severe adverse event, which should be taken into account when physicians treat HIV-positive patients with focal inflammatory bone lesions.
authors.forename: Davide
authors.initials: D
authors.lastname: Mangioni
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bandera
authors.forename: Antonio
authors.initials: A
authors.lastname: Muscatello
authors.forename: Nicola
authors.initials: N
authors.lastname: Squillace
authors.forename: Cinzia
authors.initials: C
authors.lastname: Crivellaro
authors.forename: Luca
authors.initials: L
authors.lastname: Guerra
authors.forename: Cristina
authors.initials: C
authors.lastname: Messa
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy. andrea.gori@unimib.it.
authors.forename: Andrea
authors.initials: A
authors.lastname: Gori
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001847:Bone Diseases / Q000139:chemically induced* / Q000821:virology*; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine